The global biologics contract development and manufacturing organization (CDMO) market was valued at USD 12.54 billion in 2022. It is estimated to reach USD 32.89 billion by 2031, growing at a CAGR of 11.31% during the forecast period (2023–2031). The global CDMO market penetration rate is increasing steadily, driven by increasing drug development and manufacturing outsourcing by pharma and biotech companies and ongoing divestment of non-core manufacturing facilities, adding capacity and new outsourced products to the sector.

Market Scope and Research Methodology

This report includes a m